Bambusa Therapeutics: Salvia buys 375,000 shares

A Bambusa director and ten-percent owner reported transactions in Salvia Investment GmbH shares, over which he has sole voting and dispositive power.

Available on EDGAR 11/02/2026 - 04:06 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:06 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Bambusa Therapeutics, Inc. (BBTX) reported Salvia Investment GmbH’s conversion of Series Seed Plus, Series A-1 and Series A-2 preferred stock one-for-one into common stock before the issuer’s IPO closing; the common conversion was reported as 4,769,701 shares acquired. On November 2, 2026, Salvia also purchased 375,000 common shares at $16.00 per share. The three preferred-stock rows each report zero shares remaining. Helmut Wolfgang Jeggle, a Bambusa director and ten-percent owner and Salvia’s managing director, has sole voting and dispositive power over Salvia’s shares and disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Net Buyer: 375,000 shares

Net Buy 5 txns

Insider Jeggle Helmut Wolfgang

Role Director, 10% Owner

Bought 375,000 shs ($6.00M)

Type	Security	Shares	Price	Value
Conversion	Series Seed Plus Preferred Stock F1, F2	3,135,066	$0.00	$0.00
Conversion	Series A-1 Preferred Stock F1, F2	1,473,775	$0.00	$0.00
Conversion	Series A-2 Preferred Stock F1, F2	160,860	$0.00	$0.00
Conversion	Common Stock F1, F2	4,769,701	--	--
Purchase	Common Stock F2	375,000	$16.00	$6.00M

Holdings After Transaction: Series Seed Plus Preferred Stock — 0 contracts (Indirect, See footnote); Series A-1 Preferred Stock — 0 contracts (Indirect, See footnote); Series A-2 Preferred Stock — 0 contracts (Indirect, See footnote); Common Stock — 9,264,301 shares (Indirect, See footnote)

Footnotes (2)

1. F1. All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
2. F2. Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

Key Figures

Common shares acquired in conversion: 4,769,701 shares Common shares purchased: 375,000 shares Purchase price: $16.00 per share +3 more

6 metrics

Common shares acquired in conversion 4,769,701 shares Preferred stock converted before the issuer’s IPO closing

Common shares purchased 375,000 shares November 2, 2026

Purchase price $16.00 per share Common-stock purchase on November 2, 2026

Series Seed Plus preferred shares converted 3,135,066 shares Automatic one-for-one conversion before the issuer’s IPO closing

Series A-1 preferred shares converted 1,473,775 shares Automatic one-for-one conversion before the issuer’s IPO closing

Series A-2 preferred shares converted 160,860 shares Automatic one-for-one conversion before the issuer’s IPO closing

Key Terms

one-for-one basis, dispositive power, beneficial ownership, pecuniary interest

4 terms

one-for-one basis technical

"automatically converted on a one-for-one basis"

dispositive power regulatory

"has sole voting and dispositive power"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

beneficial ownership regulatory

"disclaims beneficial ownership of such holdings"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBTX shares did Salvia buy, and at what price?

Salvia Investment GmbH purchased 375,000 common shares on November 2, 2026, at $16.00 per share. No Rule 10b5-1 plan is reported.

How many BBTX common shares came from Salvia’s preferred-stock conversion?

The conversion was reported as 4,769,701 common shares acquired. The preferred stock automatically converted one-for-one before the issuer’s IPO closing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jeggle Helmut Wolfgang

(Last) (First) (Middle)

C/O BAMBUSA THERAPEUTICS, INC.

22 BOSTON WHARF ROAD, FLOOR 7

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bambusa Therapeutics, Inc. [ BBTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		C		4,769,701	A	(1)	8,889,301	I	See footnote(2)
Common Stock	11/02/2026		P		375,000	A	$16	9,264,301	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Seed Plus Preferred Stock	(1)	11/02/2026		C			3,135,066	(1)	(1)	Common Stock	3,135,066	$0	0	I	See footnote(2)
Series A-1 Preferred Stock	(1)	11/02/2026		C			1,473,775	(1)	(1)	Common Stock	1,473,775	$0	0	I	See footnote(2)
Series A-2 Preferred Stock	(1)	11/02/2026		C			160,860	(1)	(1)	Common Stock	160,860	$0	0	I	See footnote(2)

Explanation of Responses:

1. All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

2. Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

	/s/ Jonathan I. Lieber, as attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)